Loading…
Fortress Biotech, Inc. is projected to rise to $3.05 by 2027, a +10% move from its current price of $2.76. FBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.68 | $2.76 | $2.84 | -0.04% |
| May 30 | $2.65 | $2.76 | $2.87 | -0.07% |
| May 31 | $2.63 | $2.76 | $2.89 | -0.11% |
| Jun 1 | $2.61 | $2.76 | $2.91 | -0.15% |
| Jun 2 | $2.59 | $2.75 | $2.93 | -0.19% |
| Jun 3 | $2.57 | $2.75 | $2.95 | -0.22% |
| Jun 4 | $2.56 | $2.75 | $2.96 | -0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.56 | $2.75 | $2.96 | -0.26% |
| Week 2 | $2.47 | $2.75 | $3.05 | -0.52% |
| Week 3 | $2.41 | $2.74 | $3.11 | -0.78% |
| Week 4 | $2.36 | $2.73 | $3.17 | -1.04% |
| Week 5 | $2.31 | $2.72 | $3.21 | -1.30% |
| Week 6 | $2.27 | $2.72 | $3.26 | -1.56% |
| Week 7 | $2.23 | $2.71 | $3.30 | -1.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fortress Biotech, Inc. is a healthcare company that operates as a biopharmaceutical business in the United States and internationally. Its portfolio includes Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia Ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-Hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc.
in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Fortress Biotech, Inc. trades at $2.74 per share and has a market capitalization of $91.02M, ranking 4283 by market cap. The stock carries a bullish technical backdrop with RSI14 at 60, a 50-day simple moving average of $2.54 and a 200-day simple moving average of $2.95.
Support is cited at $2.22 and resistance at $2.78, with a 30-day trading range of $2.26 to $3.32 and an annualized volatility of 60%. The year-by-year forecast shows gradual upside beginning in 2026 and extending through 2050. The 2026–2029 window delivers a steady rise in average price from $2.74 to $3.23 and a progression in ROI from 0% to 17.9%.
From 2030 onward, the average price progresses to $3.73 (ROI 36.2%), then to $7.80 by 2040 (ROI 184.6%) and $17.24 by 2050 (ROI 529.2%), with bullish sentiment indicated for the longer horizon.
A major floor 26.6% below — a decisive break under it would weaken the trend.
The nearest floor, 19.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 35.9% above — clearing it would confirm fresh momentum.
Key FBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.72 | Buy | $2.69 | Buy |
| MA 10 | $2.56 | Buy | $2.60 | Buy |
| MA 20 | $2.46 | Buy | $2.52 | Buy |
| MA 50 | $2.53 | Buy | $2.60 | Buy |
| MA 100 | $3.01 | Sell | $2.76 | Sell |
| MA 200 | $2.96 | Sell | $2.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.11 | Neutral |
| Stoch RSI (14) | 89.00 | Sell |
| CCI (20) | 131.61 | Buy |
| Williams %R (14) | -3.64 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 15.48 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 96.36 | Sell |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 73.31 | Sell |
| Momentum (10) | 0.50 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 2.81 | Sell |
| ADX (14) | 20.75 | Buy |
| ATR (14) | 0.07 | Info |
The 30-day picture shows a trading range of $2.26 to $3.32, with the current price of $2.74 sitting inside that range. RSI14 is 60, and the stock trades with a 50-day SMA of $2.54 and a 200-day SMA of $2.95. Near-term support is listed at $2.22 and resistance at $2.78, framing a relatively tight short-term corridor amid a generally bullish setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $2.76 | $3.79 | 0% | Neutral | |
| $2.41 | $3.05 | $4.09 | +10% | Neutral | |
| $2.46 | $3.19 | $4.44 | +16% | Neutral | |
| $2.56 | $3.40 | $4.87 | +23% | Bullish | |
| $2.97 | $4.03 | $5.91 | +46% | Bullish | |
| $3.59 | $4.98 | $7.45 | +80% | Bullish | |
| $3.74 | $5.26 | $8.03 | +91% | Bullish | |
| $3.89 | $5.57 | $8.65 | +102% | Bullish | |
| $3.95 | $5.75 | $9.07 | +108% | Bullish | |
| $4.00 | $5.91 | $9.47 | +114% | Bullish | |
| $5.54 | $8.76 | $14.94 | +218% | Bullish | |
| $11.08 | $19.77 | $36.90 | +616% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.22 | $2.76 | $3.25 | +0.00% |
| June 2026 | $2.33 | $2.74 | $3.30 | -0.73% |
| July 2026 | $2.25 | $2.67 | $3.25 | -2.65% |
| August 2026 | $2.28 | $2.73 | $3.36 | +2.18% |
| September 2026 | $2.34 | $2.81 | $3.49 | +3.02% |
| October 2026 | $2.32 | $2.80 | $3.50 | -0.44% |
| November 2026 | $2.34 | $2.83 | $3.58 | +1.40% |
| December 2026 | $2.45 | $2.98 | $3.79 | +5.24% |
Click any year to see its month-by-month FBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FBIO is projected to trade between $2.22 and $3.79, averaging $2.76 — a potential gain of 0% from today's $2.76. A consolidation phase looks the most probable path here.
Fortress Biotech, Inc.'s 2027 outlook centres on $3.05, within a $2.41 to $4.09 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. Price action looks broadly range-bound.
By 2028, FBIO could reach as high as $4.44, with a base case around $3.19 and support toward $2.46 — roughly +16% from $2.76. A consolidation phase looks the most probable path here.
Expect FBIO to range from $2.56 to $4.87 through 2029. The $3.40 average target implies a +23% move from current prices. That is up +7% on the projected 2028 average. Momentum favours further upside here.
The FBIO price prediction for 2030 points to an average of $4.03 (low $2.97, high $5.91) — a potential gain of +46% on today's $2.76. Buyers look set to stay in control over this stretch.
In 2031, FBIO is projected to trade between $3.59 and $7.45, averaging $4.98 — a potential gain of +80% from today's $2.76. That is up +23% on the projected 2030 average. Momentum favours further upside here.
Fortress Biotech, Inc.'s 2032 outlook centres on $5.26, within a $3.74 to $8.03 range. That is up +6% on the projected 2031 average. That marks a +91% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FBIO could reach as high as $8.65, with a base case around $5.57 and support toward $3.89 — roughly +102% from $2.76. Momentum favours further upside here.
Expect FBIO to range from $3.95 to $9.07 through 2034. The $5.75 average target implies a +108% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The FBIO price prediction for 2035 points to an average of $5.91 (low $4.00, high $9.47) — a potential gain of +114% on today's $2.76. Momentum favours further upside here.
In 2040, FBIO is projected to trade between $5.54 and $14.94, averaging $8.76 — a potential gain of +218% from today's $2.76. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fortress Biotech, Inc.'s 2050 outlook centres on $19.77, within a $11.08 to $36.90 range. That is up +126% on the projected 2040 average. That marks a +616% change versus current levels. Momentum favours further upside here.
Investing $1,000 in FBIO today (≈ 362.318841 FBIO) could be worth
$7,161.56
+$6,161.56 (+616%) by 2050 · US Dollar
Based on the average projected FBIO price of $19.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FBIOwould be worth at today's price.
$1,000 invested in FBIO on May 27, 2025 (≈ 546.448075 FBIO) would be worth
$1,508.2
+$508.2 (+50.8%) today · 1.51× · US Dollar
Based on a FBIO entry price of $1.83 vs. today's $2.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.65 | $1,041.51 | +4.2% |
| 1 month ago | $2.27 | $1,215.86 | +21.6% |
| 3 months ago | $3.52 | $784.09 | -21.6% |
| 6 months ago | $2.82 | $978.72 | -2.1% |
| 1 year ago | $1.83 | $1,508.2 | +50.8% |
| All time (5.0y) ago | $58.95 | $46.82 | -95.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FBIO forecast.
Our base-case forecast reaches $5.50 around 2033.
Implied market cap at $5.50: $182.7M
The multi-year forecast points to a pickup in price momentum beginning in 2030, with the average price rising to $3.73 and a 36.2% ROI, signaling a bullish outlook for the medium term. The upside intensifies into 2040, where the average price is projected at $7.80 with an 184.6% ROI, and again into 2050 with an average of $17.24 and a 529.2% ROI, underscoring substantial long-run appreciation potential. Earlier years (2026–2029) are characterized as neutral in sentiment, with average prices spanning roughly the mid-$2s to low-$3s and ROI ranging from 0% to 17.9%.
These figures illustrate a path of gradual growth transitioning to stronger upside in the outer horizon, subject to market dynamics and company fundamentals. These are estimates, not guarantees, and should be weighed against all investment risks.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.73 with a 36.2% ROI and bullish sentiment; the year’s min is $2.73 and max is $5.51.
The forecast turns bullish from 2030 onward, with a 2030 average of $3.73 and ROI 36.2%, rising to higher levels by 2040 and 2050 (2040 avg $7.80, ROI 184.6%; 2050 avg $17.24, ROI 529.2%). Earlier years are neutral.
Yes. The forecast shows a 2040 and 2050 path with averages and maxima well above $10; the 2050 max is $32.64.
Current price is $2.74 and market cap is $91.02M.
RSI14 is 60; SMA50 is $2.54; SMA200 is $2.95; support is $2.22 and resistance is $2.78. The 30-day range is $2.26 to $3.32.
Fortress Biotech, Inc. Community Discussion
0Share your Fortress Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.